Interim Results Of NanoVibronix's Uroshield Show Beneficial Effects For Patients

NanoVibronix Inc NAOV announced interim results of its U.K. clinical study for UroShield, a disposable ultrasound device that reduces biofilm contaminating the catheter surface.
Initial results of the independent, real-world patient study suggest changes in the microbial population diversity following the use of the Uroshield, with potential beneficial effects on the urinary and catheter microbiome.
Indwelling urinary catheters are commonly used devices to resolve urinary retention problems.
In addition to these analyses, most patients using the Uroshield reported fewer catheter blockages, infections, and other positive benefits.
Related: Health Canada Approves NanoVibronix's PainGuard, UroGuard As Licensed Devices.
The study was initiated in April 2021 to fill a gap in the Company's clinical evidence and establish documentation required by the FDA for permanent 510K clearance.
As part of the preliminary clinical study, microbiological analyses of urine and catheter samples pre- and post-use of the Uroshield device were carried out using a combination of culture, microscopy, and sequencing techniques.
Price Action: NAOV shares are down 3.95% at $0.32 on the last check Wednesday.

Momentum1.31

Growth3.72

QualityNot Available

Value37.45

Short

Medium

Long